A broad analysis of resistance development in the malaria parasite
Corey, Victoria C.
Istvan, Eva S.
Lee, Marcus C. S.
Gnädig, Nina F.
Gomez-Lorenzo, Maria G.
De Cózar, Cristina
Lafuente-Monasterio, Maria Jose
Willis, Paul A.
Goldberg, Daniel E.
Fidock, David A.
Winzeler, Elizabeth A.Note: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationCorey, V. C., A. K. Lukens, E. S. Istvan, M. C. S. Lee, V. Franco, P. Magistrado, O. Coburn-Flynn, et al. 2016. “A broad analysis of resistance development in the malaria parasite.” Nature Communications 7 (1): 11901. doi:10.1038/ncomms11901. http://dx.doi.org/10.1038/ncomms11901.
AbstractMicrobial resistance to chemotherapy has caused countless deaths where malaria is endemic. Chemotherapy may fail either due to pre-existing resistance or evolution of drug-resistant parasites. Here we use a diverse set of antimalarial compounds to investigate the acquisition of drug resistance and the degree of cross-resistance against common resistance alleles. We assess cross-resistance using a set of 15 parasite lines carrying resistance-conferring alleles in pfatp4, cytochrome bc1, pfcarl, pfdhod, pfcrt, pfmdr, pfdhfr, cytoplasmic prolyl t-RNA synthetase or hsp90. Subsequently, we assess whether resistant parasites can be obtained after several rounds of drug selection. Twenty-three of the 48 in vitro selections result in resistant parasites, with time to resistance onset ranging from 15 to 300 days. Our data indicate that pre-existing resistance may not be a major hurdle for novel-target antimalarial candidates, and focusing our attention on fast-killing compounds may result in a slower onset of clinical resistance.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27662239
- SPH Scholarly Articles